Merck receives positive EU CHMP opinion for PREVYMIS

Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of PREVYMIS for prophylaxis of cytomegalovirus disease in adult kidney transplant recipients at high risk. The CHMP has also recommended the approval for extending dosing for PREVYMIS from 100 days to 200 days following transplant in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant who are at risk for late CMV infection and disease. The CHMP’s recommendations will now be reviewed by the European Commission for marketing authorization in the European Union and a final decision is expected this year.